Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 58.55
+0.76 (1.32%)
At close: Aug 27, 2026
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 270.17M CNY in the quarter ending June 30, 2026, with 38.29% growth. This brings the company's revenue in the last twelve months to 968.83M, up 89.46% year-over-year. In the year 2025, Dizal (Jiangsu) Pharmaceutical had annual revenue of 801.14M with 122.60% growth.
Revenue (ttm)
968.83M
Revenue Growth
+89.46%
P/S Ratio
27.75
Revenue / Employee
960.19K
Employees
1,009
Market Cap
26.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 801.14M | 441.23M | 122.60% |
| Dec 31, 2024 | 359.90M | 268.61M | 294.24% |
| Dec 31, 2023 | 91.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.29M | -17.48M | -62.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 16.64B |
| Changchun High-Tech Industry (Group) | 11.02B |
| Apeloa Pharmaceutical Co.,Ltd | 9.16B |
| Zhejiang Huahai Pharmaceutical | 8.55B |
| Shijiazhuang Yiling Pharmaceutical | 7.91B |
| Dong-E-E-Jiao | 6.80B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |